Literature DB >> 15871082

[Iliofemoral and iliocaval interventions in deep venous thrombosis].

P Haage1, R W Günther.   

Abstract

Significant spontaneous thrombus disintegration in deep venous thrombosis (DVT) occurs very infrequently. On the contrary, these thrombi are prone to appositional growth and migration into the pulmonary arteries. The development of chronic venous insufficiency due to postthrombotic syndrome is a frequent consequence of DVT. Therapeutic options in DVT include anticoagulation and recanalising procedures such as thrombolysis and thrombectomy. After appropriate indication assessment, the interventional radiologist can offer an efficacy-proven minimally-invasive vessel restitution approach by performing locoregional thrombolysis, pharmacomechanical therapy or, particularly in iliocaval thrombosis, mechanical thrombectomy. These methods not only serve to restitute of vessel patency, but also allow preserving venous valve function. In DVT with recurrent pulmonary embolism, retrievable filters with extended implantation duration can be deployed. In chronic proximal venous flow obstruction or in case of significant residual stenosis after thrombolysis, balloon angioplasty with stent implantation is the treatment modality of choice. Consequently, the radiologist can adopt an important role in the treatment of extensive venous disease. In this article, the treatment modalities concerning iliofemoral and iliocaval thrombosis are demonstrated and illustrated.

Entities:  

Mesh:

Year:  2005        PMID: 15871082     DOI: 10.1055/s-2005-858061

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

1.  [Diagnostics of vascular diseases as a cause for acute abdomen].

Authors:  M S Juchems; A J Aschoff
Journal:  Radiologe       Date:  2010-03       Impact factor: 0.635

Review 2.  [Venous interventions--part 1: techniques and lower torso thromboses].

Authors:  L Kamper; K Krüger; A Altenburg; M Mansour; P Reimer; P Haage
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.